Nan Fung Trinity HK Ltd. Invests $575,000 in Climb Bio, Inc. $CLYM

Nan Fung Trinity HK Ltd. bought a new stake in shares of Climb Bio, Inc. (NASDAQ:CLYM) during the second quarter, Holdings Channel.com reports. The fund bought 463,654 shares of the company’s stock, valued at approximately $575,000.

Other large investors also recently bought and sold shares of the company. Allostery Investments LP purchased a new position in Climb Bio during the first quarter worth approximately $299,000. RA Capital Management L.P. acquired a new position in shares of Climb Bio during the 1st quarter worth approximately $38,332,000. TD Asset Management Inc acquired a new position in shares of Climb Bio during the 1st quarter worth approximately $109,000. Bank of New York Mellon Corp purchased a new position in shares of Climb Bio during the 1st quarter valued at approximately $79,000. Finally, Affinity Asset Advisors LLC acquired a new stake in Climb Bio in the 1st quarter valued at $1,830,000. Institutional investors and hedge funds own 69.76% of the company’s stock.

Climb Bio Stock Up 5.6%

Climb Bio stock opened at $1.90 on Wednesday. The company has a fifty day simple moving average of $2.07 and a 200-day simple moving average of $1.68. The firm has a market capitalization of $129.54 million, a price-to-earnings ratio of -2.50 and a beta of -0.06. Climb Bio, Inc. has a 52-week low of $1.05 and a 52-week high of $4.11.

Climb Bio (NASDAQ:CLYM) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). On average, research analysts anticipate that Climb Bio, Inc. will post -1.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on CLYM shares. Wall Street Zen lowered shares of Climb Bio from a “hold” rating to a “strong sell” rating in a report on Saturday. Robert W. Baird began coverage on shares of Climb Bio in a research note on Friday, August 15th. They set an “outperform” rating and a $9.00 target price for the company. HC Wainwright began coverage on shares of Climb Bio in a research report on Monday, October 13th. They set a “buy” rating and a $9.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Climb Bio in a research note on Wednesday, October 8th. Finally, BTIG Research reiterated a “buy” rating and set a $8.00 price objective on shares of Climb Bio in a research note on Thursday, October 16th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $9.20.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.